Antiagregación plaquetaria: stents, isquemia y sangrado ¿Qué sabemos al respecto? / Platelet antiaggregation: stents, ischemia and bleeding What do we know about it?
Rev. méd. Maule
; 37(1): 105-113, jun. 2022. tab, ilus
Article
em Es
| LILACS
| ID: biblio-1397776
Biblioteca responsável:
CL1.1
ABSTRACT
Antiplatelet therapy and percutaneous coronary intervention are two of the most important interventions in the management of coronary artery disease. In the last 20 years there has been groundbreaking advances in the pharmacotherapy and stent technology. Bleeding is the most feared complication of antiplatelet therapy, mainly due to the increase in major adverse cardiovascular events besides the bleeding itself. Different clinical decision tools have developed with the aim to define which patients have a high ischemic or bleeding risk, thus individualizing treatment.
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Inibidores da Agregação Plaquetária
/
Quimioterapia Combinada
/
Intervenção Coronária Percutânea
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
Es
Revista:
Rev. méd. Maule
Assunto da revista:
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article